6533b870fe1ef96bd12cf01d
RESEARCH PRODUCT
P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC
Indrani SarkarScott N. GettingerVictoria M. VillaflorCharles M. RudinAndrés CervantesPaul FosterAfshin DowlatiBenjamin BesseCarol O'hearBrigette B.y. MaPeter SchmidDaniel B. CostaMahrukh HuseniRebecca S. Heistsubject
0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industry03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyAtezolizumab030220 oncology & carcinogenesisInternal medicineMedicineBiomarker (medicine)Erlotinibbusinessmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2017-01-01 | Journal of Thoracic Oncology |